The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zemtsov D.S.

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Health of Russia

Esimbekova A.R.

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Health of Russia

Zinchenko I.S.

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Health of Russia

Ruksha T.G.

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Health of Russia

Antisense oligonucleotides in oncology: prospects and limitations of use in clinical practice

Authors:

Zemtsov D.S., Esimbekova A.R., Zinchenko I.S., Ruksha T.G.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2021;10(4): 59‑65

DOI: 10.17116/onkolog20211004159

Views: 2261

Downloaded: 129

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Zemtsov DS, Esimbekova AR, Zinchenko IS, Ruksha TG. Antisense oligonucleotides in oncology: prospects and limitations of use in clinical practice. P.A. Herzen Journal of Oncology. 2021;10(4):59‑65. (In Russ.)
https://doi.org/10.17116/onkolog20211004159

МСФ на ЯМ
Close metadata
Recommended articles:
Cancer awareness in the popu­lation in terms of age. P.A. Herzen Journal of Onco­logy. 2024;(2):33-38
The state of onco­logical care for the Far Eastern Fede­ral District popu­lation. Russian Journal of Preventive Medi­cine. 2024;(4):18-24
Biotechnological method for bone tissue reco­very: theoretical basis and clinical application. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(2):12-17
Biotechnology in deve­lopment of new treatments for osteoarthritis. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(2):57-60
Orga­nization and payment for mole­cular gene­tic analysis in patients with certain mali­gnancies in the constituent enti­ties of the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2025;(1):36-50
Lung tube­rculosis and mali­gnant neoplasms: the current state of the problem. Russian Journal of Preventive Medi­cine. 2025;(3):122-127

Cancers are steadily a leading cause of death in many countries of the world. The use of conventional therapies, including surgical excision, radiation, and chemotherapy, substantially increases survival rates in cancer patients. At the same time, resistance to therapy is the main cause of death in disseminated cancers. The widespread use of genome sequencing technologies has revealed considerable genetic and epigenetic changes in tumor cells, which makes it reasonable to develop new therapeutic approaches aimed at affecting individual molecules, in particular, by using antisense oligonucleotides. However, to date, the results of using these tools are very modest. The use of antisense oligonucleotide-based drugs has been approved for the treatment of Duchenne muscular dystrophy, familial amyloid neuropathy, and macular degeneration. This literature review analyzes the current state of biomedical researches aimed at using antisense oligonucleotides in oncology, the advantages, disadvantages and limitations of these methods, and the prospects for modern experimental and practical medicine.

Keywords:

antisense oligonucleotides
gene therapy
malignant neoplasms

Authors:

Zemtsov D.S.

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Health of Russia

Esimbekova A.R.

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Health of Russia

Zinchenko I.S.

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Health of Russia

Ruksha T.G.

Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Health of Russia

Received:

12.05.2021

Accepted:

17.05.2021

List of references:

  1. Alnasser SM. Review on mechanistic strategy of gene therapy in the treatment of disease. Gene. 2021;769:145246. https://doi.org/10.1016/j.gene.2020.145246
  2. Belokoneva O. Nobelpreis. Gene targeting. Nauka i zhizn’. 2007;12. Accessed April 30, 2021. (In Russ.). https://www.nkj.ru/archive/483/11798/
  3. Wang X, Xian J, Chen G, Peng H. Therapeutic oligonucleotides: a review. Sheng Wu Gong Cheng Xue Bao. 2018;34(5):664-675.  https://doi.org/10.13345/j.cjb.170401
  4. Belikova AM, Zarytova VF, Grineva NI. Synthesis of ribonucleosides and diribonucleoside phosphates containing 2-chloroethylamine and nitrogen mustard residues. Tetrahedron Lett. 1967;37:3557-3562. https://doi.org/10.1016/s0040-4039(01)89794-x
  5. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA. 1978;75(1):280-284.  https://doi.org/10.1073/pnas.75.1.280
  6. Zhou LY, Qin Z, Zhu HI, He ZY, Xu T. Current RNA-based therapeutics in clinical trials. Curr Gene Ther. 2019;19(3):172-196.  https://doi.org/10.2174/1566523219666190719100526
  7. Singh J, Kaur H, Kaushik A, Peer S. A review of antisense therapeutic interventions for molecular biological targets in various diseases. Int J Pharmacol. 2011;7(3):294-315.  https://doi.org/10.3923/ijp.2011.294.315
  8. Qiu S, Adema C, Lane T. A computational study of off-target effects of RNA interference. Nucleic Acids Res. 2005;33(6):1834-1847. https://doi.org/10.1093/nar/gki324
  9. Wang JH, Hendry BM, Sharpe CC. Silencing genes in the kidney: antisense or RNA interference? Nephrol Dial Transplant. 2008;23(7):2115-2118. https://doi.org/10.1093/ndt/gfn095
  10. Kurreck J. Antisense technologies: Improvement through novel chemical modifications. Eur J Biochem. 2003;270(8):1628-1644. https://doi.org/10.1046/j.1432-1033.2003.03555.x
  11. Bhagyashree G, Srinivasan G. Antisense oligonucleotides as therapeutics and their delivery. Curr Sci. 2017;112(3):490-498.  https://doi.org/10.18520/cs/v112/i03/490-498
  12. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther. 2002;1(5):347-355. 
  13. Turkina OR, Terakh EI. Antisence oligonucleotides. APRIORI. Series: Natural and Technical Sciences= APRIORI. Seriya: Estestvennye i tekhnicheskie nauki. 2017;3:18. (In Russ.).
  14. Bennett CF, Chiang MY, Chan H, Shoemaker JE, Mirabelli CK. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol. 1992;41(6):1023-1033.
  15. Stewart AJ, Pichon C, Meunier L, Midoux P, Monsigny M, Roche AC. Enhanced biological activity of antisense oligonucleotides complexed with glycosylated poly-L-lysine. Mol Pharmacol. 1996;50(6):1487-1494.
  16. Zobel HP, Kreuter J, Werner D, Noe CR, Kümel G, Zimmer A. Cationic polyhexylcyanoacrylate nanoparticles as carriers for antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 1997;7(5):483-493.  https://doi.org/10.1089/oli.1.1997.7.483
  17. Juliano RL, Alahari S, Kole R, Yoo H, Kole R, Cho M. Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides. Pharm Res. 1999;16(4):494-502. 
  18. Lee RG, Crosby J, Baker BF, Graham MJ, Crooke RM. Antisense technology: an emerging disease therapeutics. J Cardiovasc Transl Res. 2013;6(6):969-980.  https://doi.org/10.1007/s12265-013-9495-7
  19. Kuijper EC, Bergsma AJ, Pijnappel WWMP, Aartsma-Rus A. Opportunities and challenges for antisense oligonucleotide therapies. J Inherit Metab Dis. 2021;44(1):72-87.  https://doi.org/10.1002/jimd.12251
  20. Stix G. Shutting down a gene. Antisense drug wins approval. Sci Am. 1998;279(5):46-50.  https://doi.org/10.1038/scientificamerican1198-46b
  21. Hair P, Cameron F, McKeage K. Mipomersen sodium: first global approval. Drugs. 2013;73(5):487-493.  https://doi.org/10.1007/s40265-013-0042-2
  22. Aartsma-Rus A, Krieg AM. FDA approves Eteplirsen for Duchenne muscular dystrophy: the next chapter in the Eteplirsen saga. Nucleic Acid Ther. 2017;27(1):1-3.  https://doi.org/10.1089/nat.2016.0657
  23. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22-31.  https://doi.org/10.1056/NEJMoa1716793
  24. Aartsma-Rus A. FDA approval of Nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides. Nucleic Acid Ther. 2017;27(2):67-69.  https://doi.org/10.1089/nat.2017.0665
  25. Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11-21.  https://doi.org/10.1056/NEJMoa1716153
  26. Yang X, Lee SR, Choi YS, Alexander MO, Digenio A, Yang Q, Miller YI, Witztum JL, Tsimikas S. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. J Lipid Res. 2016;57(4):706-713.  https://doi.org/10.1194/jlr.M066399
  27. Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, Desnick R, Parker C, Phillips J, Bonkovsky HL, Vassiliou D, Penz C, Chan-Daniels A, He Q, Querbes W, Fitzgerald K, Kim JB, Garg P, Vaishnaw A, Simon AR, Anderson K. Phase 1 trial of an RNA interference therapy for acute intermittent porphyria. N Engl J Med. 2019;380(6):549-558.  https://doi.org/10.1056/NEJMoa1807838
  28. Young-A Heo. Golodirsen: First approval. Drugs. 2020;80(3):329-333.  https://doi.org/10.1007/s40265-020-01267-2
  29. Roshmi RR, Yokota T. Viltolarsen for the treatment of Duchenne muscular dystrophy. Drugs Today (Barc). 2019;55(10):627-639.  https://doi.org/10.1358/dot.2019.55.10.3045038
  30. Metelev VG, Oretskaya TS. Modified oligonucleotides: New structures, new properties, new applications. Russian Journal of Bioorganic Chemistry = Bioorganicheskaya khimiya. 2021;47(2):179-183. (In Russ.). https://doi.org/10.31857/S0132342321020172
  31. Laikova KV, Oberemok VV, Krasnodubets AM, Gal’chinsky NV, Useinov RZ, Novikov IA, Temirova ZZ, Gorlov MV, Shved NA, Kumeiko VV, Makalish TP, Bessalova EY, Fomochkina II, Esin AS, Volkov ME, Kubyshkin AV. Advances in the understanding of skin cancer: ultraviolet radiation, mutations, and antisense oligonucleotides as anticancer drugs. Molecules. 2019;24(8):1516. https://doi.org/10.3390/molecules24081516
  32. Cresce CD, Koropatnick J. Antisense treatment in human prostate cancer and melanoma. Curr Cancer Drug Targets. 2010;10(6):555-565.  https://doi.org/10.2174/156800910791859452
  33. Olie RA, Hafner C, Küttel R, Sigrist B, Willers J, Dummer R, Hall J, Stahel RA, Zangemeister-Wittke U. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. J Invest Dermatol. 2002;118(3):505-512.  https://doi.org/10.1046/j.0022-202x.2001.01677.x
  34. Shojaei F, Yazdani-Nafchi F, Banitalebi-Dehkordi M, Chehelgerdi M, Khorramian-Ghahfarokhi M. Trace of survivin in cancer. Eur J Cancer Prev. 2019;28(4):365-372.  https://doi.org/10.1097/CEJ.0000000000000453
  35. Rödel F, Frey B, Leitmann W, Capalbo G, Weiss C, Rödel C. Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys. 2008;71(1):247-255.  https://doi.org/10.1016/j.ijrobp.2008.02.011
  36. Erba HP, Sayar H, Juckett M, Lahn M, Andre V, Callies S, Schmidt S, Kadam S, Brandt JT, Van Bockstaele D, Andreeff M. Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Invest New Drugs. 2013;31(4):1023-1034. https://doi.org/10.1007/s10637-013-9935-x
  37. Choueiri TK, Hahn NM, Alva AS, Lauer RC, Dreicer R, Picus J, Pili R, Balar AV, Sonpavde G, Hoffman-Censits JH, Guancial EA, Alter R, Regan MM, Jacobs C, Stewart PS, Pal SK, Rosenberg JE. The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (Apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer. J Clin Oncol. 2014;32(15 suppl):tps4593. https://doi.org/10.1200/jco.2014.32.15_suppl.tps4593
  38. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, Blum W, DiNardo CD, Kadia T, Dunbar M, Kirby R. et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106-1117. https://doi.org/10.1158/2159-8290.CD-16-0313
  39. Activity and safety of front-line venetoclax and rituximab in roung and fit patients with chronic lymphocytic leukemia (VeRitAs). Accessed May 5, 2021. https://clinicaltrials.gov/ct2/show/NCT03455517?term=AON&recrs=ad&cond=Cancer&draw=2&rank=1
  40. Watts JK, Ockene IS. RNA interference for the masses? siRNA targeting PCSK9 promises prevention of cardiovascular disease. Nucleic Acid Ther. 2020;30:1-3.  https://doi.org/10.1089/nat.2019.0835
  41. A randomized controlled phase II trial with intradermal IMO-2125 in pathological tumor stage (p) T3-4 cN0M0 melanoma (INTRIM). Accessed May 5, 2021. https://clinicaltrials.gov/ct2/show/NCT04126876?term=ODN&draw=3&rank=14
  42. SD-101, Nnvolumab, and radiation therapy in treating patients with chemotherapy-refractory metastatic pancreatic cancer. Accessed May 5, 2021. https://clinicaltrials.gov/ct2/show/NCT04050085?term=ODN&draw=3&rank=20
  43. Ruksha TG, Gyrylova SN, Aksenenko MB. Malignant skin neoplasms: analysis of the incidence rate in the Krasnoyarsk territory, problems of prevention and improvement of early diagnostics. Vestnik dermatologii i venerologii. 2010(4):4-9. (In Russ.).
  44. Bedi D, Gillespie JW, Petrenko VA Jr, Ebner A, Leitner M, Hinterdorfer P, Petrenko. Targeted delivery of siRNA into breast cancer cells via phage fusion proteins. Mol Pharm. 2013;10(2):551-559.  https://doi.org/10.1021/mp3006006
  45. Sardone V, Zhou H, Muntoni F, Ferlini A, Falzarano MS. Antisense oligonucleotide-based therapy for neuromuscular disease. Molecules. 2017;22(4):563.  https://doi.org/10.3390/molecules22040563
  46. Le BT, Raguraman P, Kosbar TR, Fletcher S, Wilton SD, Veedu RN. Antisense oligonucleotides targeting angiogenic factors as potential cancer therapeutics. Mol Ther Nucleic Acids. 2019;14:142-157.  https://doi.org/10.1016/j.omtn.2018.11.007

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.